Nymox Pharmaceutical Corporation(NYMXF.US)

Company Encyclopedia
View More
name
Nymox Pharmaceutical Corporation
NYMXF.US
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease.
1.899 T
NYMXF.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pre-market hot trades in US stocks: Synchrony Financial pre-market down 9.38%; Allogene Therapeutics pre-market up 9.36%

    Synchrony Financial pre-market down 9.38%; Allogene Therapeutics pre-market up 9.36%; Ping An Biomedical pre-market up 66.95%; Intelligent Bio Solutions pre-market up 53.46%; Signing Day Sports pre-market up 30.46%

    Tracking Unusual Activity·
    US
    SYF
    -0.96%
    US
    ALLO
    +14.77%
    Tracking Unusual Activity·
    US
    SYF
    -0.96%
    US
    ALLO
    +14.77%

    Peer-Reviewed Study Establishes Consistent Quality and Early Clinical Success of Ossium’s Proprietary Off-the-Shelf Bone Marrow

    A peer-reviewed study published in Cytotherapy highlights the early clinical success of Ossium Health's cryopreserved bone marrow as an off-the-shelf graft for allogeneic hematopoietic cell transplantation. The study demonstrates that Ossium's GMP-manufactured bone marrow can be produced consistently and delivered quickly, overcoming the logistical challenges of fresh grafts. Clinical results from three high-risk AML patients showed rapid engraftment and no adverse events, reinforcing the biological potency of Ossium's approach. This research challenges the assumption that fresh grafts are superior, paving the way for more predictable access to life-saving therapies.

    MorningStar·
    MorningStar·

    U.S. stock movement quick report: Acrivon up nearly 19%, Erasca down over 14%, tech stocks active

    Overview of the US Stock Market In the past hour, the US stock market has shown a clear characteristic of sector rotation, with notable performances from technology and pharmaceutical stocks. In terms of capital flow, investors seem to favor short-term opportunities, particularly looking for breakthroughs in small-cap stocks and thematic stocks. The market pace is fast, volatility has increased, and short-term enthusiasm has significantly risen. The stock with the largest movement in the past hour, Acrivon Therapeutics, leads the market with a 18.98% increase, demonstrating strong capital momentum. The stock's upward trend is steady, attracting a large amount of short-term capital attention, making it the market focus. Strong stocks: 1. Polestar Automotive UK PLC - CW 27: up 17.56%, performing impressively in the automotive sector, with active short-term capital involvement. 2. Next Tech: up 13.01%, benefiting from a favorable market atmosphere due to the active performance of the technology sector. 3. Trident Digital Tech: up 8.41%, with continued heat in the digital technology field driving stock price upward. 4. Aerovironment: up 7.23%, showing clear signs of recovery in the aviation sector, attracting investors' attention. 5. RTX: up 4.79%, with stable performance in the defense technology sector providing support. 6. Ondas: up 3.78%, with innovations in the communication technology field sparking market interest

    Tracking Unusual Activity·
    US
    ACRV
    -9.33%
    Tracking Unusual Activity·
    US
    ACRV
    -9.33%

    After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates

    Several biotechnology and healthcare companies saw significant after-hours gains on Wednesday due to clinical updates and financial results. ALX Oncology Holdings (ALXO) surged 10.17% after positive Phase 2 trial data. Globus Medical (GMED) climbed 9.34% on strong preliminary sales results, while Acrivon Therapeutics (ACRV) rose 6.44% ahead of upcoming clinical data releases. Other notable gainers included RenovoRx (RNXT), AnaptysBio (ANAB), Omeros Corp (OMER), EUDA Health (EUDA), TherapeuticsMD (TXMD), and Pyxis Oncology (PYXS).

    rttnews·
    US
    GMED
    -0.16%
    US
    ALXO
    +8.87%
    US
    ACRV
    -9.33%
    rttnews·
    US
    GMED
    -0.16%
    US
    ALXO
    +8.87%
    US
    ACRV
    -9.33%

    Health Care Up Amid Deal Activity -- Health Care Roundup

    Health-care companies rose amid deal activity. Biopharmaceutical company AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines. Shares of obesity-drug maker Eli Lilly rose, testing all-time highs. Trump administration officials made sweeping changes to U.S. federal dietary guidelines, recommending that people avoid highly processed foods, dramatically increase protein intake and skip added sugar. Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires 01-07-26 1846ET

    marketscreener·
    US
    ABBV
    -1.81%
    US
    LLY
    -1.99%
    marketscreener·
    US
    ABBV
    -1.81%
    US
    LLY
    -1.99%
    © 2026 Longbridge｜Disclaimer